Education
About Us
Working with TipRanks
Follow Us
Illumina (ILMN)
NASDAQ:ILMN
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.01Last Year’s EPS
0.36Same Quarter Last Year
Moderate Buy
Based on 20 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 5.82%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with strong performance in certain areas like NovaSeq X placements and innovation pipeline advancements, but significant challenges in the Greater China region, research funding uncertainty, and tariff impacts. While growth areas show promise, the lowlights pose substantial risks.Company Guidance
During the Illumina First Quarter 2025 earnings call, the company provided updated guidance reflecting significant macroeconomic challenges, including geopolitical tensions and funding uncertainties. The company revised its revenue expectations, anticipating a decline of 3% to 1% year-over-year, with specific guidance for the Greater China region due to export restrictions impacting instrument placements. Despite these headwinds, Illumina reported Q1 revenue of $1.04 billion, at the upper end of its guidance, with EPS of $0.97. The company is focused on achieving long-term financial goals, including high single-digit revenue growth and 500 basis point margin expansions by 2027. Illumina is implementing a $100 million cost reduction program to mitigate the impact of new U.S. tariffs, which are projected to cost the company $85 million in 2025. The guidance reflects confidence in the resilience of its core business, excluding Greater China, anticipating flat to 2% growth outside this region.Strong Performance of NovaSeq X Instruments
NovaSeq X instruments exceeded expectations with over 60 placements in Q1, following more than 90 placements in Q4. The transition to X continues to progress well, particularly among clinical customers.
Innovation Pipeline Advancements
Illumina announced a new spatial offering with significantly larger capture area, higher resolution, and greater sensitivity. Early customer feedback for this offering has been very positive.
Robust Sequencing Activity
Total sequencing gigabase output on connected high and mid throughput instruments grew at a rate of more than 30% year-over-year, with strong growth from both clinical and research customers.
Cost Reduction Initiatives
Illumina executed a $100 million cost reduction program to address macroeconomic challenges, realizing partial benefits in Q1 and expecting full savings in 2025.
---
ILMN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ILMN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $79.58 | $75.76 | -4.80% |
Feb 06, 2025 | $122.80 | $111.06 | -9.56% |
Nov 04, 2024 | $153.49 | $154.96 | +0.96% |
Aug 06, 2024 | $116.36 | $121.10 | +4.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Illumina (ILMN) report earnings?
Illumina (ILMN) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Illumina (ILMN) earnings time?
Illumina (ILMN) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ILMN EPS forecast?
ILMN EPS forecast for the fiscal quarter 2025 (Q2) is 1.01.
---
